Infinity Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Infinity Pharmaceuticals

14/11/2022 14:40

* Infinity Pharmaceuticals Inc  INFI.OQ  reported a
quarterly
adjusted loss of 12 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 6 cents per share.
    * Revenue rose 66.4% to $712.00 thousand from a year ago;
analysts
expected $6.19 million. 
    * Infinity Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 12 cents​.
    * The mean earnings estimate of analysts had risen by
about 23.1%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Infinity Pharmaceuticals Inc shares had held steady so far
this
quarter and lost 47.1% so far this year.
    * The company reported a quarterly loss of $10.72 million.
    * Wall Street's median 12-month price target for Infinity
Pharmaceuticals Inc is $3.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 02:40 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.06          -0.12          Missed
 Jun. 30 2022      -0.15          -0.13          Beat
 Mar. 31 2022      -0.13          -0.14          Missed
 Dec. 31 2021      -0.13          -0.13          Met